{{item.title}}
{{item.text}}
{{item.title}}
{{item.text}}
PwC MoneyTree™
PwC MoneyTree is the go-to source for Venture Capital firms and high-growth startups.
The PwC MoneyTree website is home to the PwC/CB Insights quarterly MoneyTree Report. It contains historical trend data beginning with 1995, updates on the Venture Capital and high-growth startups ecosystem, and relevant insights from PwC’s emerging company services and venture capital tax, audit and advisory professionals. The PwC/CB Insights MoneyTree Report is the definitive source of information on venture capital investments in emerging companies. This study is a staple of the financial community, entrepreneurs, government policymakers and the business press worldwide.
US MoneyTree Report
During the third quarter of 2018, VC-backed companies based in the United States saw a 17% increase in funding, bringing up the total dollar amount invested to $28B. US private companies raised 6 $500M+ and 55 $100M+ VC rounds, the most of any quarter on record.
PwC and CB Insights' Healthcare MoneyTree report brings you a quarterly publication based on US venture capital funding for healthcare related industries. Each issue is broken out by five key sections: US healthcare trends, US healthcare industries, US healthcare places, US healthcare movers and shakers, and Global healthcare trends.
Explore the data
Current quarter investment data
View current quarter investment data by Sector, State, Region or Stage of Development.
The MoneyTree Report website only provides aggregate level data.
For company level information, please contact our provider, CB Insights, at info@cbinsights.com.
Explore current quarter dataHistorical trend investment data
View detailed results for the most recent quarter and aggregate trend data, beginning with 2002.
The MoneyTree Report website only provides aggregate level data.
For company level information, please contact our provider, CB Insights, at info@cbinsights.com.
Explore historical trend dataThis quarter approached quarterly funding records, with $27.5B invested in VC-backed startups and 55 mega-rounds. On the other hand, VC-backed deal volume is down to a level unseen since Q4 of 2012. As early-stage startups wonder if there are adequate funds available, the overall deal volume (1,229) still reflects a healthy startup ecosystem.
{{filterContent.facetedTitle}}
{{contentList.dataService.numberHits}} {{contentList.dataService.numberHits == 1 ? 'result' : 'results'}}
{{contentList.loadingText}}
{{contentList.loadingText}}
{{filterContent.facetedTitle}}
{{contentList.dataService.numberHits}} {{contentList.dataService.numberHits == 1 ? 'result' : 'results'}}
{{contentList.loadingText}}
{{item.title}}
{{item.text}}
{{item.title}}
{{item.text}}
{{contentList.loadingText}}
Contact us
Tom Ciccolella
US Assurance, Partner, PwC US
Tel: +1 (408) 817 5979
Email
David Silverman
National Emerging Company Services Practice Co-Leader, PwC US
Tel: +1 (646) 471 5421
Email
Mark McCaffrey
US Technology, Media and Telecommunications Leader, PwC US
Tel: +1 (408) 817 4199
Email
Danny Wallace
National Emerging Company Services Practice Co-Leader, PwC US
Tel: +1 (408) 817 5030
Email
Greg Vlahos
Partner, US Pharmaceuticals and Life Sciences , PwC US
Tel: +1 (408) 817 5029
Email
Follow us
